Equities

Perspective Therapeutics Inc

Perspective Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)10.72
  • Today's Change-0.03 / -0.28%
  • Shares traded811.49k
  • 1 Year change+65.10%
  • Beta1.4690
Data delayed at least 15 minutes, as of Jul 05 2024 21:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. It is also developing imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.

  • Revenue in USD (TTM)-304.00k
  • Net income in USD-48.91m
  • Incorporated2018
  • Employees116.00
  • Location
    Perspective Therapeutics Inc2401 Elliott Avenue, Suite 320SEATTLE 98121United StatesUSA
  • Phone+1 (206) 676-0900
  • Fax+1 (302) 636-5454
  • Websitehttps://isoray.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Wave Life Sciences Ltd112.91m-61.67m669.94m266.00--26.35--5.93-0.5152-0.51520.99850.27190.4494----424,488.70-24.54-56.98-60.43-102.38-----54.61-353.20----0.00--3,005.1051.0464.46---35.44--
AnaptysBio Inc22.96m-163.30m676.14m117.00--14.15--29.45-6.13-6.130.8621.750.048--5.33196,256.40-34.11-18.08-36.72-18.96-----711.18-269.21----0.00--66.7827.97-27.11---5.36--
Stoke Therapeutics Inc7.85m-108.53m683.81m110.00--4.35--87.17-2.42-2.420.17473.020.0322--31.1971,318.18-44.57-31.62-51.70-33.92-----1,383.40-1,775.50----0.00---29.22---3.59--11.56--
Praxis Precision Medicines Inc2.20m-125.38m689.79m82.00--2.33--314.26-15.91-15.910.239417.320.0126----26,768.29-71.89-74.04-83.56-85.12-----5,711.85-24,589.25----0.00------42.40---4.52--
Hillevax Inc0.00-143.51m699.08m90.00--2.89-----3.29-3.290.004.870.00----0.00-46.66---50.34--------------0.0963------22.68------
CARGO Therapeutics Inc0.00-121.21m704.67m116.00--1.62-----2.91-2.910.009.48------0.00--------------------0.00-------139.67------
SS Innovations International Inc11.22m-22.75m708.57m239.00--52.35--63.16-0.1372-0.13720.06980.07930.6146--2.4346,943.05-124.63-161.38-289.30-449.7611.08-79.79-202.80-495.770.8699-57.410.3901-------846.31--159.31--
Immunome Inc12.68m-232.03m721.43m55.00--2.51--56.88-5.49-5.490.42734.780.069----230,600.00-126.15-94.54-148.61-112.66-----1,829.44-1,403.15----0.00-------184.68--29.52--
Perspective Therapeutics Inc-304.00k-48.91m722.30m116.00--2.74-----1.62-1.97-0.00923.92-0.0015-----2,620.69-24.10---25.46--------------0.0074--------------
Savara Inc0.00-64.49m728.40m37.00--5.02-----0.3848-0.38480.000.88190.00----0.00-44.84-36.86-47.26-39.54-------102,587.50----0.1782-------43.38--15.91--
Ginkgo Bioworks Holdings Inc208.70m-853.81m737.46m1.22k--0.687--3.53-0.4347-0.43470.10610.48550.1044--3.82171,344.00-42.70---46.94--80.43---409.12------0.00---47.36--57.58------
89bio Inc0.00-165.03m739.85m70.00--1.40-----2.01-2.010.005.360.00----0.00-30.80-45.50-32.70-49.31------------0.0466-------39.37---36.58--
Dianthus Therapeutics Inc3.22m-50.21m740.19m53.00--1.99--229.59-3.20-3.200.272112.700.0138----60,830.19-21.56-41.40-22.27-44.70-----1,557.51-12,132.27----0.00------43.04---57.21--
Nuvation Bio Inc0.00-68.87m748.93m159.00--1.12-----0.3146-0.31460.002.710.00----0.00-10.84-16.27-11.09-16.65------------0.00------27.25------
Viridian Therapeutics Inc288.00k-218.13m786.29m96.00--2.05--2,730.18-4.50-4.500.00589.130.0006--2.503,063.83-42.89-55.59-45.38-60.32-----75,737.84-5,678.12----0.0337---82.28-48.16-83.05--15.08--
Data as of Jul 05 2024. Currency figures normalised to Perspective Therapeutics Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.